The DOI matches its Crossref record.
Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-and multiple-dose administration to normal volunteers
Abstract
The pharmacokinetics and safety of the L-valyl ester pro-drug of acyclovir, valaciclovir (256U87), were investigated in two phase I, placebo-controlled trials in normal volunteers. These included a single-dose study with doses from 100 to 1000 mg (single cohort) and a multiple-dose investigation with doses from 250 to 2000 mg (five separate cohorts). In each cohort, eight subjects received valaciclovir and four subjects received placebo. Pharmacokinetic findings for valaciclovir and acyclovir were consistent in the two studies. Valaciclovir was rapidly and extensively converted to acyclovir, resulting in significantly greater acyclovir bioavailability (approximately threefold to fivefold) compared with that historically observed with high-dose (800 mg) oral acyclovir. At the higher valaciclovir doses, acyclovir maximum concentration and daily area under the concentration-time curve approximated those obtained with intravenous acyclovir. The favorable safety profile and enhanced acyclovir bioavailability from valaciclovir administration has prompted additional clinical evaluations for zoster and herpes simplex virus treatment, as well as cytomegalovirus suppression in immunocompromised patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation
Lowance, D., Neumayer, H.-H., Legendre, C. M., Squifflet, J.-P., Kovarik, J., Brennan, P. J., Norman, D., Mendez, R., Keating, M. R., Coggon, G. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401903 · Cited by 712
Beutner, K. R., Friedman, D. J., Forszpaniak, C., Andersen, P. L., & Wood, M. J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.7.1546 · Cited by 613
Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and Management
Piret, J., & Boivin, G. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00615-10 · Cited by 558
Seley-Radtke, K. L., & Yates, M. K. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.04.004 · Cited by 543
Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections
Odumade, O. A., Hogquist, K. A., & Balfour, H. H. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00044-10 · Cited by 458
Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy
De Clercq, E., & Field, H. J. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706446 · Cited by 336
Soul-Lawton, J., Seaber, E., On, N., Wootton, R., Rolan, P., & Posner, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2759 · Cited by 315
Han, H.-K., de Vrueh, R. L. A., Rhie, J. K., Covitz, K.-M. Y., Smith, P. L., Lee, C.-P., Oh, D.-M., Sadee, W., & Amidon1, G. L. (1998) · Pharmaceutical Research · doi:10.1023/a:1011919319810 · Cited by 297
Sjögren, E., Abrahamsson, B., Augustijns, P., Becker, D., Bolger, M. B., Brewster, M., Brouwers, J., Flanagan, T., Harwood, M., Heinen, C., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.010 · Cited by 279
Reitano, M., Tyring, S., Lang, W., Thoming, C., Worm, A. ‐., Borelli, S., Chambers, L. O., Robinson, J. M., Corey, L., & the International Valaciclovir HSV Study Group (1998) · The Journal of Infectious Diseases · doi:10.1086/515385 · Cited by 209
Studahl, M., Lindquist, L., Eriksson, B.-M., Günther, G., Bengner, M., Franzen-Röhl, E., Fohlman, J., Bergström, T., & Aurelius, E. (2013) · Drugs · doi:10.1007/s40265-013-0007-5 · Cited by 90
ROMANOWSKI, B., MARINA, R. B., & ROBERTS, J. N. (2003) · Sexually Transmitted Diseases · doi:10.1097/00007435-200303000-00010 · Cited by 56
Metadata
- Authors
- Weller, S., Blum, M. R., Doucette, M., Burnette, T., Cederberg, D. M., de Miranda, P., & Smiley, M. L.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1993-12
- Volume
- 54
- Issue
- 6
- Pages
- 595-605
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2025975417
- Cited by
- 395
- References
- 0
- FWCI
- 15.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.